€3bn heartburn for AstraZeneca

Drug firm AstraZeneca saw almost €3bn wiped off its value today after it lost a key patent on best-selling heartburn treatment Nexium.

€3bn heartburn for AstraZeneca

Drug firm AstraZeneca saw almost €3bn wiped off its value today after it lost a key patent on best-selling heartburn treatment Nexium.

AstraZeneca said it was “disappointed” with the decision by the European Patent Office (EPO) to withdraw the patent for Nexium.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited